Article Versions Notes

Shimizu K, Sunagawa Y, Funamoto M, Honda H, Katanasaka Y, Murai N, Kawase Y, Hirako Y, Katagiri T, Yabe H, et al. The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway. Pharmaceuticals. 2021; 14(12):1268. https://doi.org/10.3390/ph14121268

Shimizu, Kana, Yoichi Sunagawa, Masafumi Funamoto, Hiroki Honda, Yasufumi Katanasaka, Noriyuki Murai, Yuto Kawase, Yuta Hirako, Takahiro Katagiri, Harumi Yabe, and et al. 2021. "The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway" Pharmaceuticals 14, no. 12: 1268. https://doi.org/10.3390/ph14121268

Shimizu, K., Sunagawa, Y., Funamoto, M., Honda, H., Katanasaka, Y., Murai, N., Kawase, Y., Hirako, Y., Katagiri, T., Yabe, H., Shimizu, S., Sari, N., Wada, H., Hasegawa, K., & Morimoto, T. (2021). The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway. Pharmaceuticals, 14(12), 1268. https://doi.org/10.3390/ph14121268